Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy

G. A.Amos Burke; Auke Beishuizen; Deepa Bhojwani; Birgit Burkhardt; Véronique Minard-Colin; Robin E. Norris; Edita Kabickova; F. Guclu Pinarli; Nurdan Tacyildiz; Angela Howes; Jan de Jong; Grace Liu; Kerri Nottage; Mariya Salman; Xavier Woot de Trixhe; Mitchell Cairo

doi:10.1038/s41375-020-0749-5

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy

G. A.Amos Burke^*, Auke Beishuizen, Deepa Bhojwani, Birgit Burkhardt, Véronique Minard-Colin, Robin E. Norris, Edita Kabickova, F. Guclu Pinarli, Nurdan Tacyildiz, Angela Howes, Jan de Jong, Grace Liu, Kerri Nottage, Mariya Salman, Xavier Woot de Trixhe, Mitchell Cairo

^*Corresponding author for this work

Cancer and Genomic Sciences

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2271-2275
Number of pages	5
Journal	Leukemia
Volume	34
Issue number	8
DOIs	https://doi.org/10.1038/s41375-020-0749-5
Publication status	Published - 1 Aug 2020

Bibliographical note

Funding Information:
Conflict of interest GAAB has received consultancy fees from Jans-sen, Merck, Takeda, and Roche. BB did not receive personal fees, but her institution received consultancy fees from Janssen, Roche, ADC Therapeutics, Novartis, and Celgene. AH, JdJ, KN, and MS hold Johnson & Johnson stock and are employed by Janssen R&D. GL and XWdT are also employees of Janssen. MC has received research funding from Janssen. AB, DB, VM-C, REN, EK, FGP, and NT have no conflicts of interest to disclose.

Funding Information:
Acknowledgements Sponsored by Janssen Research & Development, LLC. Support for pharmacokinetic and pharmacodynamic assessments was provided by Martine Neyens and Sriram Balasubramanian, respectively, Janssen Research & Development, LLC. Additional data quality control and manuscript review were provided by Madeliene Curtis, Janssen Research & Development, LLC. Writing assistance was provided by Liqing Xiao and Sally Hassan of Parexel and funded by Janssen Global Services, LLC. The authors would also like to thank the patients who participated in this trial, and their families, as well as the investigators, study coordinators, study teams, and nurses.

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-020-0749-5

Cite this

Burke, G. A. A., Beishuizen, A., Bhojwani, D., Burkhardt, B., Minard-Colin, V., Norris, R. E., Kabickova, E., Pinarli, F. G., Tacyildiz, N., Howes, A., Jong, J. D., Liu, G., Nottage, K., Salman, M., Trixhe, X. W. D., & Cairo, M. (2020). Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Leukemia, 34(8), 2271-2275. https://doi.org/10.1038/s41375-020-0749-5

@article{741a05d9dbe944a7b219e6a58bd25455,

title = "Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy",

author = "Burke, {G. A.Amos} and Auke Beishuizen and Deepa Bhojwani and Birgit Burkhardt and V{\'e}ronique Minard-Colin and Norris, {Robin E.} and Edita Kabickova and Pinarli, {F. Guclu} and Nurdan Tacyildiz and Angela Howes and Jong, {Jan de} and Grace Liu and Kerri Nottage and Mariya Salman and Trixhe, {Xavier Woot de} and Mitchell Cairo",

note = "Funding Information: Conflict of interest GAAB has received consultancy fees from Jans-sen, Merck, Takeda, and Roche. BB did not receive personal fees, but her institution received consultancy fees from Janssen, Roche, ADC Therapeutics, Novartis, and Celgene. AH, JdJ, KN, and MS hold Johnson & Johnson stock and are employed by Janssen R&D. GL and XWdT are also employees of Janssen. MC has received research funding from Janssen. AB, DB, VM-C, REN, EK, FGP, and NT have no conflicts of interest to disclose. Funding Information: Acknowledgements Sponsored by Janssen Research & Development, LLC. Support for pharmacokinetic and pharmacodynamic assessments was provided by Martine Neyens and Sriram Balasubramanian, respectively, Janssen Research & Development, LLC. Additional data quality control and manuscript review were provided by Madeliene Curtis, Janssen Research & Development, LLC. Writing assistance was provided by Liqing Xiao and Sally Hassan of Parexel and funded by Janssen Global Services, LLC. The authors would also like to thank the patients who participated in this trial, and their families, as well as the investigators, study coordinators, study teams, and nurses.",

year = "2020",

month = aug,

day = "1",

doi = "10.1038/s41375-020-0749-5",

language = "English",

volume = "34",

pages = "2271--2275",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "8",

}

Burke, GAA, Beishuizen, A, Bhojwani, D, Burkhardt, B, Minard-Colin, V, Norris, RE, Kabickova, E, Pinarli, FG, Tacyildiz, N, Howes, A, Jong, JD, Liu, G, Nottage, K, Salman, M, Trixhe, XWD & Cairo, M 2020, 'Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy', Leukemia, vol. 34, no. 8, pp. 2271-2275. https://doi.org/10.1038/s41375-020-0749-5

TY - JOUR

T1 - Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial)

T2 - initial safety, pharmacokinetics, and efficacy

AU - Burke, G. A.Amos

AU - Beishuizen, Auke

AU - Bhojwani, Deepa

AU - Burkhardt, Birgit

AU - Minard-Colin, Véronique

AU - Norris, Robin E.

AU - Kabickova, Edita

AU - Pinarli, F. Guclu

AU - Tacyildiz, Nurdan

AU - Howes, Angela

AU - Jong, Jan de

AU - Liu, Grace

AU - Nottage, Kerri

AU - Salman, Mariya

AU - Trixhe, Xavier Woot de

AU - Cairo, Mitchell

N1 - Funding Information: Conflict of interest GAAB has received consultancy fees from Jans-sen, Merck, Takeda, and Roche. BB did not receive personal fees, but her institution received consultancy fees from Janssen, Roche, ADC Therapeutics, Novartis, and Celgene. AH, JdJ, KN, and MS hold Johnson & Johnson stock and are employed by Janssen R&D. GL and XWdT are also employees of Janssen. MC has received research funding from Janssen. AB, DB, VM-C, REN, EK, FGP, and NT have no conflicts of interest to disclose. Funding Information: Acknowledgements Sponsored by Janssen Research & Development, LLC. Support for pharmacokinetic and pharmacodynamic assessments was provided by Martine Neyens and Sriram Balasubramanian, respectively, Janssen Research & Development, LLC. Additional data quality control and manuscript review were provided by Madeliene Curtis, Janssen Research & Development, LLC. Writing assistance was provided by Liqing Xiao and Sally Hassan of Parexel and funded by Janssen Global Services, LLC. The authors would also like to thank the patients who participated in this trial, and their families, as well as the investigators, study coordinators, study teams, and nurses.

PY - 2020/8/1

Y1 - 2020/8/1

UR - http://www.scopus.com/inward/record.url?scp=85079822301&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0749-5

DO - 10.1038/s41375-020-0749-5

M3 - Letter

C2 - 32071430

AN - SCOPUS:85079822301

SN - 0887-6924

VL - 34

SP - 2271

EP - 2275

JO - Leukemia

JF - Leukemia

IS - 8

ER -